Examkin

Soru

Zorluk: OrtaHemodynamic and Coagulation Processes

A 41-year-old woman is brought to the emergency department by her partner due to progressive confusion, fatigue, and the appearance of small red spots on her legs over the past three days. Her medical history is unremarkable, and she takes no medications. Vital signs are temperature 38.2°C (100.8°F), blood pressure 145/88 mmHg, heart rate 112/min, and respiratory rate 18/min. Physical examination reveals scleral icterus, diffuse petechiae over the lower extremities, and disorientation to time and place.

Initial laboratory studies show:
- Hemoglobin: 7.6 g/dL
- Platelet count: 22,000/mm³
- Leukocyte count: 8,500/mm³
- Creatinine: 1.4 mg/dL
- Total bilirubin: 3.2 mg/dL (Indirect: 2.8 mg/dL)
- Prothrombin time (PT): 12 seconds
- Activated partial thromboplastin time (aPTT): 28 seconds

Arrange the following diagnostic and therapeutic steps in the most appropriate chronological sequence for managing this patient's condition.

  1. 1Evaluate a peripheral blood smear for the presence of schistocytes.
  2. 2Collect a blood sample for ADAMTS13 activity and inhibitor assays.
  3. 3Initiate emergent therapeutic plasma exchange (PLEX).
  4. 4Monitor daily platelet counts and lactate dehydrogenase (LDH) levels.

Cevap

The correct sequence is to first evaluate the peripheral blood smear, then collect the ADAMTS13 assay, followed by initiating therapeutic plasma exchange (PLEX), and finally monitoring daily platelet counts and LDH levels to assess response.
In a patient presenting with suspected thrombotic thrombocytopenic purpura (TTP), the first critical step is to rapidly confirm the presence of microangiopathic hemolytic anemia (MAHA) by evaluating a peripheral blood smear for schistocytes. Once MAHA and thrombocytopenia are confirmed clinically, TTP is the presumptive diagnosis. It is mandatory to draw a blood sample for the ADAMTS13 activity assay next, strictly before any plasma therapy is given. Because donor plasma contains functional ADAMTS13, receiving plasma before the assay is drawn will falsely normalize the patient's test results. After securing the unadulterated diagnostic sample, the priority shifts to treatment. Therapeutic plasma exchange (PLEX) is initiated immediately as the primary life-saving intervention to remove pathogenic autoantibodies and replace the deficient enzyme. Finally, once PLEX is underway, the patient's ongoing clinical response must be tracked by monitoring daily platelet counts and LDH levels until the consumptive and hemolytic processes resolve.

Adım Adım Çözüm

1
Recognize the clinical presentation of suspected thrombotic thrombocytopenic purpura (TTP).
The patient exhibits neurologic symptoms, fever, severe thrombocytopenia, and evidence of hemolytic anemia with normal coagulation times.
Identifying the disease process is required to select the precise diagnostic and treatment pathway.
2
Confirm the presence of microangiopathic hemolytic anemia (MAHA).
Evaluate a peripheral blood smear for schistocytes.
MAHA and thrombocytopenia are the two core criteria required to presumptively diagnose TTP and justify initiating life-saving treatment.
3
Obtain baseline diagnostic labs that would be definitively altered by therapeutic interventions.
Draw blood for ADAMTS13 activity and inhibitor levels.
Administering therapeutic plasma (which contains functional ADAMTS13) before this blood draw will yield false-negative results, obscuring the definitive diagnosis.
4
Initiate primary therapy followed by continuous assessment.
Begin therapeutic plasma exchange (PLEX), then monitor daily platelet counts and LDH.
PLEX is the definitive initial treatment for TTP. Tracking hemolysis markers determines when the microangiopathic process has arrested.

Anahtar Kavram

The management of Thrombotic Thrombocytopenic Purpura (TTP) requires establishing the diagnosis with a peripheral smear, strictly drawing an ADAMTS13 assay prior to plasma exposure, initiating PLEX emergently, and tracking response via hemolysis markers.
Bu soruyu puanla

Konular

Hemodynamic and Coagulation Processes

Bu konudan daha fazla soru